The IIF designation was added to include cystic lesions that are slightly more complex than category II, but that do not fulfill criteria of category III.
BCAN announces awardee of its first-ever bladder cancer career development award
Roger Li, MD, Moffit Cancer Center, was awarded the grant to study the novel oncolytic virus drug CG0070 in patients with intermediate-risk non–muscle-invasive bladder cancer.
Speaking of Urology: ASCO GU 2023 Highlights
Laura Bukavina, MD, and Kyle Rose, MD, discuss some of the notable abstracts from the 2023 ASCO GU conference.
New studies and specialty clinics at University Hospitals look at FPMRS, OAB, and more
"UH is working on starting clinics throughout rural Northeast Ohio, and we're meeting to develop a FPMRS program, both virtual and in-person, so patients can have access to this point of care," says David Sheyn, MD.
Dr. Katherine Rotker on destigmatizing sexual health
"I think there's a lot of fear that can go into talking about these topics," says Katherine Rotker, MD.
Dr. Xu discusses treatment selection across therapy lines in renal cell carcinoma
“Now in 2023, it’s really a question of how to apply these agents and which combinations to use in the first line,” said Vincent (Wenxin) Xu, MD.
Enzalutamide plus leuprolide boosts metastasis-free survival in nmHSPC
The enzalutamide/leuprolide combo also led to statistically significant improvements in time to PSA progression and time to start of new antineoplastic therapy.
2 Clarke Drive Cranbury, NJ 08512